Wells Fargo Begins Coverage of Illumina with Outperform Rating GenomeWeb Smaller opportunities, Evans said, include HLA typing, idiopathic disease, and preventive medicine. On the competitive front, he took note of Life Tech's delay in the launch of its PII chip, which has provided Illumina time to "consider a competitive ... |
